World J Mens Health.  2018 Sep;36(3):183-191. 10.5534/wjmh.180005.

Dehydroepiandrosterone and Erectile Function: A Review

• El-Sakka A

• KMID: 2419319
• DOI: http://doi.org/10.5534/wjmh.180005

Abstract

To review the contemporary knowledge regarding the dehydroepiandrosterone and erectile function. Medline was reviewed for English-language journal articles spanning the time between January 1990 and December 2017, using the terms "˜erectile function', "˜dehydroepiandrosterone'. We used original articles and review articles that found to be relevant to the purpose of this review. Criteria included all pertinent review articles, randomized controlled trials with tight methodological design, cohort studies and retrospective analyses. We also manually revised references from selected articles. Several interesting studies have addressed the age-related decline in dehydroepiandrosterone levels with many age-related phenomena or deterioration in various physiological functions. Particularly, aging; neurological functions including decreased well-being, cognition, and memory; increased depression, decreased bone mineral density, obesity, diabetes, increased cardiovascular morbidity, erectile dysfunction (ED), and decreased libido. Supporting this result, some trials of dehydroepiandrosterone supplementation in healthy, middle-aged, and elderly subjects have reported improvements in different aspects of well-being. Several studies had demonstrated that dehydroepiandrosterone level is declined as a part of aging. Large-scale well-designed prospective studies are warranted to better define indications and therapeutic implications of dehydroepiandrosterone in men with ED.

Keyword

Androgens; Dehydroepiandrosterone; Erectile dysfunction; Testosterone

MeSH Terms

Aged
Aging
Androgens
Bone Density
Cognition
Cohort Studies
Dehydroepiandrosterone*
Depression
Erectile Dysfunction
Humans
Libido
Male
Memory
Obesity
Prospective Studies
Retrospective Studies
Testosterone
Androgens
Dehydroepiandrosterone
Testosterone

Reference

1. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab. 1984; 59:551–555. PMID: 6235241.

2. Genazzani AD, Lanzoni C, Genazzani AR. Might DHEA be considered a beneficial replacement therapy in the elderly? Drugs Aging. 2007; 24:173–185. PMID: 17362047.

3. Gurnell EM, Chatterjee VK. Dehydroepiandrosterone replacement therapy. Eur J Endocrinol. 2001; 145:103–106. PMID: 11454504.

4. Johnson MD, Bebb RA, Sirrs SM. Uses of DHEA in aging and other disease states. Ageing Res Rev. 2002; 1:29–41. PMID: 12039447.

5. Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab. 1994; 78:1360–1367. PMID: 7515387.

6. El-Sakka AI, Hassoba HM. Age related testosterone depletion in patients with erectile dysfunction. J Urol. 2006; 176:2589–2593. PMID: 17085165.

7. Walther A, Mahler F, Debelak R, Ehlert U. Psychobiological protective factors modifying the association between age and sexual health in men: findings from the men's health 40+ study. Am J Mens Health. 2017; 11:737–747. PMID: 28413941.

8. Pastuszak AW, Moon YM, Scovell J, Badal J, Lamb DJ, Link RE, et al. Poor sleep quality predicts hypogonadal symptoms and sexual dysfunction in male nonstandard shift workers. Urology. 2017; 102:121–125. PMID: 27988267.

9. Baulieu EE. Dehydroepiandrosterone (DHEA): a fountain of youth? J Clin Endocrinol Metab. 1996; 81:3147–3151. PMID: 8784058.

10. Labrie F, Bélanger A, Cusan L, Candas B. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. J Clin Endocrinol Metab. 1997; 82:2403–2409. PMID: 9253308.

11. Labrie F, Bélanger A, Luu-The V, Labrie C, Simard J, Cusan L, et al. DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids. 1998; 63:322–328. PMID: 9618795.

12. Kawano H, Yasue H, Kitagawa A, Hirai N, Yoshida T, Soejima H, et al. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab. 2003; 88:3190–3195. PMID: 12843164.

13. Williams MR, Dawood T, Ling S, Dai A, Lew R, Myles K, et al. Dehydroepiandrosterone increases endothelial cell proliferation in vitro and improves endothelial function in vivo by mechanisms independent of androgen and estrogen receptors. J Clin Endocrinol Metab. 2004; 89:4708–4715. PMID: 15356084.

14. Simoncini T, Mannella P, Fornari L, Varone G, Caruso A, Genazzani AR. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology. 2003; 144:3449–3455. PMID: 12865324.

15. Liu D, Iruthayanathan M, Homan LL, Wang Y, Yang L, Wang Y, et al. Dehydroepiandrosterone stimulates endothelial proliferation and angiogenesis through extracellular signal-regulated kinase 1/2-mediated mechanisms. Endocrinology. 2008; 149:889–898. PMID: 18079198.

16. Liu D, Si H, Reynolds KA, Zhen W, Jia Z, Dillon JS. Dehydroepiandrosterone protects vascular endothelial cells against apoptosis through a Galphai protein-dependent activation of phosphatidylinositol 3-kinase/Akt and regulation of antiapoptotic Bcl-2 expression. Endocrinology. 2007; 148:3068–3076. PMID: 17395704.

17. Chen H, Lin AS, Li Y, Reiter CE, Ver MR, Quon MJ. Dehydroepiandrosterone stimulates phosphorylation of FoxO1 in vascular endothelial cells via phosphatidylinositol 3-kinase- and protein kinase A-dependent signaling pathways to regulate ET-1 synthesis and secretion. J Biol Chem. 2008; 283:29228–29238. PMID: 18718910.

18. Trivedi DP, Khaw KT. Dehydroepiandrosterone sulfate and mortality in elderly men and women. J Clin Endocrinol Metab. 2001; 86:4171–4177. PMID: 11549645.

19. Tilvis RS, Kähönen M, Härkönen M. Dehydroepiandrosterone sulfate, diseases and mortality in a general aged population. Aging (Milano). 1999; 11:30–34. PMID: 10337439.

20. Liu D, Dillon JS. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). J Biol Chem. 2002; 277:21379–21388. PMID: 11934890.

21. Williams MR, Ling S, Dawood T, Hashimura K, Dai A, Li H, et al. Dehydroepiandrosterone inhibits human vascular smooth muscle cell proliferation independent of ARs and ERs. J Clin Endocrinol Metab. 2002; 87:176–181. PMID: 11788644.

22. Farrukh IS, Peng W, Orlinska U, Hoidal JR. Effect of dehydroepiandrosterone on hypoxic pulmonary vasoconstriction: a Ca(2+)-activated K(+)-channel opener. Am J Physiol. 1998; 274:L186–L195. PMID: 9486202.

23. Liu D, Dillon JS. Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptor. Steroids. 2004; 69:279–289. PMID: 15183694.

24. Lugg JA, González-Cadavid NF, Rajfer J. The role of nitric oxide in erectile function. J Androl. 1995; 16:2–4. PMID: 7539414.

25. Penson DF, Ng C, Cai L, Rajfer J, González-Cadavid NF. Androgen and pituitary control of penile nitric oxide synthase and erectile function in the rat. Biol Reprod. 1996; 55:567–574. PMID: 8862773.

26. Rand MJ, Li CG. Nitric oxide as a neurotransmitter in peripheral nerves: nature of transmitter and mechanism of transmission. Annu Rev Physiol. 1995; 57:659–682. PMID: 7539992.

27. Penson DF, Ng C, Rajfer J, Gonzalez-Cadavid NF. Adrenal control of erectile function and nitric oxide synthase in the rat penis. Endocrinology. 1997; 138:3925–3932. PMID: 9275083.

28. Oka M, Karoor V, Homma N, Nagaoka T, Sakao E, Golembeski SM, et al. Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension. Cardiovasc Res. 2007; 74:377–387. PMID: 17346686.

29. Lee SY, Myung SC, Lee MY, Kim TH, Kim SC, Kim KD, et al. The effects of dehydroepiandrosterone (DHEA)/DHEA-sulfate (DHEAS) on the contraction responses of the clitoral cavernous smooth muscle from female rabbits. J Sex Med. 2009; 6:2653–2660. PMID: 19627466.

30. Basar MM, Aydin G, Mert HC, Keles I, Caglayan O, Orkun S, et al. Relationship between serum sex steroids and Aging Male Symptoms score and International Index of Erectile Function. Urology. 2005; 66:597–601. PMID: 16140085.

31. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994; 151:54–61. PMID: 8254833.

32. Panjari M, Davis SR. DHEA therapy for women: effect on sexual function and wellbeing. Hum Reprod Update. 2007; 13:239–248. PMID: 17208951.

33. Reiter WJ, Pycha A, Schatzl G, Klingler HC, Märk I, Auterith A, et al. Serum dehydroepiandrosterone sulfate concentrations in men with erectile dysfunction. Urology. 2000; 55:755–758. PMID: 10792095.

34. Reiter WJ, Schatzl G, Märk I, Zeiner A, Pycha A, Marberger M. Dehydroepiandrosterone in the treatment of erectile dysfunction in patients with different organic etiologies. Urol Res. 2001; 29:278–281. PMID: 11585284.

35. Morales A, Black A, Emerson L, Barkin J, Kuzmarov I, Day A. Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male. 2009; 12:104–112. PMID: 19883295.

36. Sachs BD, Liu YC. Maintenance of erection of penile glans, but not penile body, after transection of rat cavernous nerves. J Urol. 1991; 146:900–905. PMID: 1875517.

37. Shealy CN. A review of dehydroepiandrosterone (DHEA). Integr Physiol Behav Sci. 1995; 30:308–313. PMID: 8788227.

38. Munarriz R, Talakoub L, Flaherty E, Gioia M, Hoag L, Kim NN, et al. Androgen replacement therapy with dehydroepiandrosterone for androgen insufficiency and female sexual dysfunction: androgen and questionnaire results. J Sex Marital Ther. 2002; 28(Suppl 1):165–173.

39. Walther A, Ehlert U. Steroid secretion and psychological well-being in men 40+. In : Rice TR, Sher L, editors. Neurobiology of men's mental health. New York (NY): Nova;2015. p. 287–322.

40. Zhao SG, Wang JM, Han QF, Li T, Yao HC. Association between sildenafil and inflammation markers/mediators. Int J Cardiol. 2015; 198:178–179. PMID: 26163912.

41. Morales A, Heaton JP, Carson CC 3rd. Andropause: a misnomer for a true clinical entity. J Urol. 2000; 163:705–712. PMID: 10687961.

42. Tekdogan U, Tuncel A, Tuglu D, Basar MM, Atan A. Effect of sildenafil citrate treatment on serum dehydroepiandrosterone sulfate levels in patients with erectile dysfunction. Urology. 2006; 68:626–630. PMID: 16979704.

43. Nair KS, Rizza RA, O'Brien P, Dhatariya K, Short KR, Nehra A, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med. 2006; 355:1647–1659. PMID: 17050889.

44. Saad F, Hoesl CE, Oettel M, Fauteck JD, Römmler A. Dehydroepiandrosterone treatment in the aging male: what should the urologist know? Eur Urol. 2005; 48:724–733. PMID: 16137821.

45. Eich DM, Nestler JE, Johnson DE, Dworkin GH, Ko D, Wechsler AS, et al. Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation. 1993; 87:261–269. PMID: 8419015.

46. Bernini G, Versari D, Moretti A, Virdis A, Ghiadoni L, Bardini M, et al. Vascular reactivity in congenital hypogonadal men before and after testosterone replacement therapy. J Clin Endocrinol Metab. 2006; 91:1691–1697. PMID: 16492703.

47. Løvås K, Gebre-Medhin G, Trovik TS, Fougner KJ, Uhlving S, Nedrebø BG, et al. Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial. J Clin Endocrinol Metab. 2003; 88:1112–1118. PMID: 12629093.

48. Hunt PJ, Gurnell EM, Huppert FA, Richards C, Prevost AT, Wass JA, et al. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison’s disease in a randomized, double blind trial. J Clin Endocrinol Metab. 2000; 85:4650–4656. PMID: 11134123.

49. Achermann JC, Silverman BL. Dehydroepiandrosterone replacement for patients with adrenal insufficiency. Lancet. 2001; 357:1381–1382. PMID: 11356430.

50. Parasrampuria J, Schwartz K, Petesch R. Quality control of dehydroepiandrosterone dietary supplement products. JAMA. 1998; 280:1565.

51. Thompson RD, Carlson M, Thompson RD, Carlson M. Liquid chromatographic determination of dehydroepiandrosterone (DHEA) in dietary supplement products. J AOAC Int. 2000; 83:847–857. PMID: 10995111.

52. Mola JR. Erectile dysfunction in the older adult male. Urol Nurs. 2015; 35:87–93. PMID: 26197627.

53. Capogrosso P, Montorsi F, Salonia A. Erectile dysfunction in young patients is a proxy of overall men's health status. Curr Opin Urol. 2016; 26:140–145. PMID: 26716563.

54. Samaras N, Samaras D, Frangos E, Forster A, Philippe J. A review of age-related dehydroepiandrosterone decline and its association with well-known geriatric syndromes: is treatment beneficial? Rejuvenation Res. 2013; 16:285–294. PMID: 23647054.

55. Valenti G, Denti L, Maggio M, Ceda G, Volpato S, Bandinelli S, et al. Effect of DHEAS on skeletal muscle over the life span: the InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2004; 59:466–472. PMID: 15123757.

56. Bischoff-Ferrari HA, Orav EJ, Dawson-Hughes B. Additive benefit of higher testosterone levels and vitamin D plus calcium supplementation in regard to fall risk reduction among older men and women. Osteoporos Int. 2008; 19:1307–1314. PMID: 18351428.

57. Feldman HA, Johannes CB, Araujo AB, Mohr BA, Longcope C, McKinlay JB. Low dehydroepiandrosterone and ischemic heart disease in middle-aged men: prospective results from the Massachusetts Male Aging Study. Am J Epidemiol. 2001; 153:79–89. PMID: 11159150.

58. Yoshida S, Aihara K, Azuma H, Uemoto R, Sumitomo-Ueda Y, Yagi S, et al. Dehydroepiandrosterone sulfate is inversely associated with sex-dependent diverse carotid atherosclerosis regardless of endothelial function. Atherosclerosis. 2010; 212:310–315. PMID: 20627295.

59. Jankowska EA, Biel B, Majda J, Szklarska A, Lopuszanska M, Medras M, et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation. 2006; 114:1829–1837. PMID: 17030678.

60. Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol. 2011; 165:687–701. PMID: 21852391.

61. Michael A, Jenaway A, Paykel ES, Herbert J. Altered salivary dehydroepiandrosterone levels in major depression in adults. Biol Psychiatry. 2000; 48:989–995. PMID: 11082473.

62. Schmidt PJ, Daly RC, Bloch M, Smith MJ, Danaceau MA, St Clair LS, et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry. 2005; 62:154–162. PMID: 15699292.

63. Genazzani AR, Stomati M, Valentino V, Pluchino N, Pot E, Casarosa E, et al. Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric. 2011; 14:661–668. PMID: 21942655.

64. El-Sakka AI, Sayed HM, Tayeb KA. Type 2 diabetes-associated androgen alteration in patients with erectile dysfunction. Int J Androl. 2008; 31:602–608. PMID: 17877718.

65. El-Sakka AI, Sayed HM, Tayeb KA. Androgen pattern in patients with type 2 diabetes-associated erectile dysfunction: impact of metabolic control. Urology. 2009; 74:552–559. PMID: 19592073.

66. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003; 6:1–7. PMID: 12809074.

67. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab. 2004; 89:5462–5468. PMID: 15531498.

68. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2002; 87:589–598. PMID: 11836290.

69. Rabijewski M, Papierska L, Kuczerowski R, Piątkiewicz P. Hormonal determinants of erectile dysfunction and lower urinary tract symptoms in middle-aged and elderly men with prediabetes. Aging Male. 2015; 18:256–264. PMID: 26444448.

70. Samaras N, Papadopoulou MA, Samaras D, Ongaro F. Offlabel use of hormones as an antiaging strategy: a review. Clin Interv Aging. 2014; 9:1175–1186. PMID: 25092967.

71. Komesaroff PA. Unravelling the enigma of dehydroepiandrosterone: moving forward step by step. Endocrinology. 2008; 149:886–888. PMID: 18292199.

72. El-Sakka AI. Dehydroepiandrosterone and testosterone: effects on erectile function. In : Watson RR, editor. DHEA(Dehydroepiandrosterone) in human health and aging. Boca Raton (FL): Taylor & Francis Group LLC;2011. p. 351–362.